No results for ‘’
Glaxosmithkline Pharmaceuticals Ltd
₹2346.80
(1.78%)
Mon, 25 May 2026, 10:00 pm
Health Technology
Pharmaceuticals: Major
24.5KGlaxosmithkline Pharmaceuticals Shareholding
| Shareholders | MAR 2026 | DEC 2025 | SEPT 2025 | JUN 2025 | MAR 2025 |
|---|---|---|---|---|---|
| Promoters | 75 | 75 | 75 | 75 | 75 |
| FII | 4.62 | 4.64 | 4.79 | 4.88 | 4.52 |
| DII | 7.68 | 7.70 | 7.75 | 7.70 | 7.79 |
| Public | 12.70 | 12.66 | 12.45 | 12.41 | 12.69 |
| Government | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Glaxosmithkline Pharmaceuticals Ltd Shareholding Pattern
The Glaxosmithkline Pharmaceuticals Ltd shareholding pattern provides detailed insights into how ownership of the company is distributed among promoters, FIIs, DIIs, public investors, and government entities. Tracking the Glaxosmithkline Pharmaceuticals Ltd shareholding structure helps investors understand institutional confidence, promoter commitment, and overall market sentiment.
Glaxosmithkline Pharmaceuticals Ltd (NSE: GLAXO, BSE: 500660) operates in the Health technology sector and Pharmaceuticals: major industry. Monitoring the Glaxosmithkline Pharmaceuticals Ltd shareholding pattern regularly allows investors to analyze ownership trends and make informed investment decisions.
Glaxosmithkline Pharmaceuticals Ltd Shareholding Pattern (Latest)
The latest Glaxosmithkline Pharmaceuticals Ltd shareholding for Mar 2026 is:
- Promoters: 75%
- FII: 4.62%
- DII: 7.68%
- Public: 12.70%
- Government: 0.00%
Promoter holding in Glaxosmithkline Pharmaceuticals Ltd remains stable, reflecting consistent long-term commitment.
Glaxosmithkline Pharmaceuticals Ltd Promoter Holding Trend
Promoter shareholding plays a crucial role in evaluating management confidence in Glaxosmithkline Pharmaceuticals Ltd.
- Mar 2026: 75%
- Dec 2025: 75%
- Sept 2025: 75%
- Jun 2025: 75%
- Mar 2025: 75%
Promoter stake remains largely stable, showing consistent ownership structure.
Glaxosmithkline Pharmaceuticals Ltd FII Shareholding Trend
Foreign Institutional Investors (FIIs) reflect global investor sentiment toward Glaxosmithkline Pharmaceuticals Ltd.
- Mar 2026: 4.62%
- Dec 2025: 4.64%
- Sept 2025: 4.79%
- Jun 2025: 4.88%
- Mar 2025: 4.52%
FII holding has declined, suggesting cautious sentiment among foreign investors.
Glaxosmithkline Pharmaceuticals Ltd DII Shareholding Trend
Domestic Institutional Investors (DIIs) include mutual funds, banks, and insurance companies.
- Mar 2026: 7.68%
- Dec 2025: 7.70%
- Sept 2025: 7.75%
- Jun 2025: 7.70%
- Mar 2025: 7.79%
DII holdings remain stable, reflecting steady institutional participation.
Glaxosmithkline Pharmaceuticals Ltd Public Shareholding Trend
Public shareholding represents retail and non-institutional investors.
- Mar 2026: 12.70%
- Dec 2025: 12.66%
- Sept 2025: 12.45%
- Jun 2025: 12.41%
- Mar 2025: 12.69%
Public participation in Glaxosmithkline Pharmaceuticals Ltd has increased, indicating rising retail investor interest.
Glaxosmithkline Pharmaceuticals Ltd Government Holding
Government holding in Glaxosmithkline Pharmaceuticals Ltd currently stands at 0.00%.
Glaxosmithkline Pharmaceuticals Ltd operates without significant government ownership.
Glaxosmithkline Pharmaceuticals Ltd Shareholding Analysis Summary
The Glaxosmithkline Pharmaceuticals Ltd shareholding pattern highlights the ownership structure and investor confidence in the company. Stable promoter holdings combined with institutional participation often indicate strong fundamentals and long-term growth potential.
Glaxosmithkline Pharmaceuticals Ltd shows strong promoter and domestic institutional confidence, which is positive for long-term investors.
Regular monitoring of the Glaxosmithkline Pharmaceuticals Ltd shareholding helps investors understand market confidence, institutional activity, and potential future stock movements.